Long-term follow-up of axillary recurrences after negative sentinel lymph node biopsy: effect on prognosis and survival

Bulte, J.P.; Wely, Bob J. van; Kasper, Stefan; Kuijt, G.P.; Wildenberg, Frits J. H. van den; Strobbe, Luc J. A.; Wilt, Johannes H. W. de

doi:10.1007/s10549-013-2608-9

Cited by 11 publications

(8 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bulte et al presented the data of 51 patients with isolated axillary relapses, which shows that almost 50% developed distant metastases. In these cases, ER negativity was a poor prognostic factor 6 . In our study, 56% of patients with lymph node relapse suffered from distant metastases and 32% were diagnosed no more than 3 months after regional relapse.…”

Section: Discussionsupporting

confidence: 48%

“…In these cases, ER negativity was a poor prognostic factor. 6 In our study, 56% of patients with lymph node relapse suffered from distant metastases and 32% were diagnosed no more than 3 months after regional relapse.…”

Section: Ta B L E 2 Coxproportional-hazards Regression For Locoregionmentioning

confidence: 48%

“…Locoregional relapses (LRR) after negative SLNB are infrequent, occurring in up to 3% of patients 1 . Up to 50% of those patients develop distant metastases concomitantly or after relapse 6 . We sought to define risk factors for LRR after negative SLNB in breast cancer patients and risk factors for developing distant metastases following LRR.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Locoregional relapse is a strong prognostic indicator of distant metastatic progression in breast cancer patients after negative sentinel lymph node biopsy

Falco¹,

Masojć²,

Kram³

2020

Breast J

View full text Add to dashboard Cite

Purpose: Sentinel lymph node biopsy is routinely used in breast cancer patients with clinically negative axillary lymph nodes. Locoregional relapses after negative sentinel lymph node biopsy are infrequent, occurring in up to 3% of patients. Methods: Six thousand and eight patients underwent breast cancer surgery in our center between 2006 and 2015. We analyzed 1466 patients with negative sentinel lymph node biopsy and no prior systemic treatment. Mastectomy without irradiation was used in 25.4% of these patients and breast-conserving surgery with adjuvant radiotherapy in 74.6%. Forty-seven (3.21%) locoregional relapses were identified within a median of 51 months (10-138 months). The molecular type was analyzed as a risk factor for locoregional relapses and distant metastases. The locoregional relapse location was then analyzed as a risk factor for distant metastases. Results: Triple-negative breast cancer (P = .003), age <40 year (P = .007), multifocality (P = .011), and mastectomy (P < .0001) were risk factors for locoregional relapses. Patients who developed locoregional relapses more frequently developed distant metastases (P < .0001). The distribution of molecular types did not differ significantly in patients with locoregional relapses and distant metastases, concentrating in triple-negative and Luminal B tumor cases with distant metastases in almost 58% of cases, while not occurring in Luminal A patients. The locoregional-to-distant metastasis interval was shorter in cases of chest wall and lymph nodes relapse compared with breast-only relapse locations(P = .028). Conclusion: Molecular type, especially triple-negative, young age, mastectomy without adjuvant irradiation, and multifocality are risk factors for locoregional relapse in sentinel lymph node biopsy negative breast cancer patients. Locoregional relapse is an important risk factor for developing distant metastasis, except in Luminal A breast cancer patients and those who suffer from breast-only relapse.

show abstract

Section: Discussionsupporting

confidence: 48%

Section: Ta B L E 2 Coxproportional-hazards Regression For Locoregionmentioning

confidence: 48%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Locoregional relapse is a strong prognostic indicator of distant metastatic progression in breast cancer patients after negative sentinel lymph node biopsy

Falco¹,

Masojć²,

Kram³

2020

Breast J

View full text Add to dashboard Cite

show abstract

“…Speers et al [17] showed no difference in the SF 2Gy value among different molecular types of breast cancer, with values ranging from 17% to 77%. They defined tumours with SF 2Gy 0.45 or below to be radiation sensitive [18]. For the purpose of this study, we set also the value of SF 2Gy to 0.45 for radiation sensitive tumours, which means that 45% of breast cancer cells survive every fraction of 2-Gy irradiation.…”

Section: Discussionmentioning

confidence: 99%

Molecular type and maximal metastasis diameter influence risk of axillary recurrence in breast cancer patients after positive sentinel lymph node biopsy

Falco¹,

Masojć²,

Kram³

2021

Rep Pract Oncol Radiother.

View full text Add to dashboard Cite

“…Although sentinel lymph node biopsy (SLNB) was proposed in the mid-1990s as a minimally invasive, sensitive tool for axillary staging in breast cancer patients and the technique allows axillary lymph node dissection to be avoided if the sentinel lymph node is negative, axillary recurrences after negative SLNB still occur. A recent epidemiology study performed by Bulte et al 6 identified 54 patients with an axillary recurrence at a median of 30 months (range, 3-79 months) after SLNB. Therefore, in this initial small series, we did not perform SLNB; instead, axillary lymph node dissection was performed.…”

Section: Discussionmentioning

confidence: 99%

Single Incision for Quadrantectomy and Laparoscopic Axillary Lymph Node Dissection in the Treatment of Early Breast Cancer: Initial Experience of 5 Cases

Fan

Kong

et al. 2014

Journal of Laparoendoscopic & Advanced Surgical Techniques

View full text Add to dashboard Cite

show abstract

Long-term follow-up of axillary recurrences after negative sentinel lymph node biopsy: effect on prognosis and survival

Cited by 11 publications

References 19 publications

Locoregional relapse is a strong prognostic indicator of distant metastatic progression in breast cancer patients after negative sentinel lymph node biopsy

Locoregional relapse is a strong prognostic indicator of distant metastatic progression in breast cancer patients after negative sentinel lymph node biopsy

Molecular type and maximal metastasis diameter influence risk of axillary recurrence in breast cancer patients after positive sentinel lymph node biopsy

Single Incision for Quadrantectomy and Laparoscopic Axillary Lymph Node Dissection in the Treatment of Early Breast Cancer: Initial Experience of 5 Cases

Contact Info

Product

Resources

About